Compare MLCI & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLCI | CPHI |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | China |
| Employees | 21 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.6M | 31.2M |
| IPO Year | N/A | 2008 |
| Metric | MLCI | CPHI |
|---|---|---|
| Price | $3.41 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.1K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,144,268.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.68 | $0.38 |
| 52 Week High | $8.68 | $2.00 |
| Indicator | MLCI | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 41.41 |
| Support Level | $3.31 | $0.52 |
| Resistance Level | $3.84 | $0.68 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 58.76 | 11.20 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.